机译:Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and IDH1 R132C mutation
机译:Pediatric cancer and hematopoietic stem cell transplantation patients requiring renal replacement therapy: results of the retrospective nationwide AIEOP study
机译:Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study
机译:Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study
机译:Clinical features and treatment outcomes for primary cutaneous CD4+small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review
机译:Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group
机译:Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine
机译:The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation
机译:Role of high acquisition flow cytometry in the detection of marrow involvement in patients with extramedullary B cell non-Hodgkins lymphoma: a comparison with marrow aspirate cytology, trephine biopsy, and PET
机译:Investigating the potential molecular players and therapeutic drug molecules in carfilzomib resistant multiple myeloma by comprehensive bioinformatics analysis
机译:Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission
机译:Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia